Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease

Journal of Inherited Metabolic Disease

Volumn 38, Issue 2, 2015, Pages 305-314

  van Gelder, Carin M ^a   Hoogeveen Westerveld, Marianne ^a   Kroos, Marian A ^a   Plug, Iris ^a   van der Ploeg, Ans T ^a   Reuser, Arnold J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE; ANTIBODY; BIOLOGICAL MARKER; GAA PROTEIN, HUMAN; RECOMBINANT PROTEIN;

AGE; BLOOD; CELL CULTURE; DEFICIENCY; DISEASE COURSE; ENZYME REPLACEMENT; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; GLYCOGEN STORAGE DISEASE TYPE II; HUMAN; IMMUNOLOGY; INFANT; MALE; MORTALITY; MUTATION; NETHERLANDS; NEWBORN; PHENOTYPE; PRESCHOOL CHILD; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; ALPHA-GLUCOSIDASES; ANTIBODIES; BIOMARKERS; CELLS, CULTURED; CHILD, PRESCHOOL; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; NETHERLANDS; PHENOTYPE; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TRANSFECTION; TREATMENT OUTCOME;

EID: 84897362437     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9707-6     Document Type: Article

References (40)

1. Abbott M, Prater SN, Banugaria SG et al (2011) Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol Genet Metab 104:583–586
2. Al Khallaf HH, Propst J, Geffrard S et al (2013) CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy. JIMD Rep 9:133–137
3. Bali DS, Goldstein JL, Banugaria S et al (2012) Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C: Semin Med Genet 160:40–49
4. Banugaria SG, Prater SN, Ng Y-K et al (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13:729–736
5. Banugaria SG, Prater SN, McGann JK et al (2013a) Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 15:123–131
6. Banugaria SG, Prater SN, Patel TT et al (2013b) Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. PloS One 8:e67052
7. Brooks DA (1999) Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol Genet Metab 68:268–275
8. Brooks DA, Kakavanos R, Hopwood JJ (2003) Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 9:450–453
9. Chakrapani A, Vellodi A, Robinson P et al (2010) Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 33:747–750
10. De Vries JM, van der Beek NAME, Kroos MA et al (2010) High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101:338–345
11. Dierenfeld AD, McEntee MF, Vogler C a, et al (2010) Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2:60ra89.
12. Güngör D, Reuser AJJ (2013) How to describe the clinical spectrum in Pompe disease? Am J Med Genet A 161A:399–400
13. Hermans MM, Kroos MA, Smeitink JA et al (1998) Glycogen Storage Disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry. Hum Mutat 11:209–215
14. Hirschhorn R, Reuser AJJ (2001) Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, Valle D, Sly W (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New-York, pp 3389–3420
15. Hunley TE, Corzo D, Dudek M et al (2004) Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 114:e532–e535
16. Kishnani PS, Hwu W-L, Mandel H et al (2006a) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671–676
17. Kishnani PS, Nicolino M, Voit T et al (2006b) Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 149:89–97
18. Kishnani PS, Corzo D, Nicolino M et al (2007) Recombinant human acid α-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68:99–109
19. Kishnani PS, Corzo D, Leslie ND et al (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66:329–335
20. Kishnani PS, Goldenberg PC, DeArmey SL et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26–33
21. Klinge L, Straub V, Neudorf U et al (2005a) Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 15:24–31
22. Klinge L, Straub V, Neudorf U, Voit T (2005b) Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics 36:6–11
23. Kroos MA, Waitfield AE, Joosse M et al (1997) A novel acid alpha-glucosidase mutation identified in a Pakistani family with glycogen storage disease type II. J Inherit Metab Dis 20:556–558
24. Kroos MA, Pomponio RJ, Hagemans ML et al (2007) Broad spectrum of Pompe disease in patients with the same c.-32-13T- > G haplotype. Neurology 68:110–115
25. Lacaná E, Yao LP, Pariser AR, Rosenberg AMYS (2012) The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C: Semin Med Genet 160:30–39
26. Matzinger P (2002) The danger model: a renewed sense of self. Science 296:301–305
27. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS (2009) Elimination of antibodies to recombinant enzyme in Pompe’s disease. N Engl J Med 360:194–195
28. Messinger YH, Mendelsohn NJ, Rhead W et al (2012) Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14:135–142
29. Nicolino M, Byrne B, Wraith JE et al (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11:210–219
30. Patel TT, Banugaria SG, Case LE et al (2012) The impact of antibodies in late-onset Pompe disease: A case series and literature review. Mol Genet Metab 106:301–309
31. Piper M, Darrah J (1994) Motor assessment of the developing infant. Saunders, Philadelphia
32. Poutanen T, Jokinen E (2007) Left ventricular mass in 169 healthy children and young adults assessed by three-dimensional echocardiography. Pediatr Cardiol 28:201–207
33. Regnery C, Kornblum C, Hanisch F et al (2012) 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35:837–845
34. Van den Hout H, Reuser AJJ, Vulto AG et al (2000) Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356:397–398
35. Van den Hout HMP, Hop W, van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340
36. Van den Hout JMP, Kamphoven JHJ, Winkel LP et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457
37. Van der Ploeg AT, Reuser AJJ (2008) Pompe’s disease. Lancet 372:1342–1353
38. Van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 362:1396–1406
39. Van Gelder CM, Kroos MA, Ozkan L, et al (2012) Antibody formation to enzyme therapy in classic infantile Pompe disease: Implications of patient age. J Inherit Metab Dis 35 Suppl 1:S12.
40. Wang J, Lozier J, Johnson G et al (2008) Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol 26:901–908